Library · Digestive & liver · Treatment of acromegaly and neuroendocrine tumors
Lanreotide
Somatuline, BIM-23014, DC-13-116
Synthetic octapeptide analog of somatostatin from the 1980s, designed to outlast the natural hormone’s short half-life. Approved and widely used (Depot/Autogel) for acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, with monthly dosing improving compliance over earlier analogs.
Research score 95/100. Reference only, not a dose.
- Hormone Regulation
- Gut Health
- Anti-cancer
- Appetite Suppression
- Somatostatin Analog
- US status
- Prescription Only
- Approval
- FDA + EMA Approved
- Evidence
- FDA-approved Somatostatin analog (Somatuline). Standard of care for acromegaly and neuroendocrine tumors (NETs).
- Research score
- 95 / 100
- Indication
- Multiple Approved Indications
- Origin
- France
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Binds somatostatin receptors SSTR2 and SSTR5 with high affinity, triggering inhibitory G-protein signaling that cuts calcium influx and hormone release (GH, IGF-1, GI peptides); in neuroendocrine tumors it also curbs cell proliferation via PI3K/Akt suppression and reduces tumor blood vessel formation by lowering VEGF.
Safety file
GI disturbances (diarrhea, nausea, abdominal pain) are very common; gallstones with prolonged use, injection-site nodules, and possible bradycardia or hyperglycemia.
- Injection site reactions
- Gastrointestinal disturbances
- Gallstones
- Hyperglycemia
- Thyroid function changes
- Bradycardia